Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer: results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials

BACKGROUND: The National Epirubicin Adjuvant Trial (NEAT) and BR9601 trials tested the benefit of epirubicin when added to cyclophosphamide, methotrexate and 5-fluorouracil (E-CMF) compared with standard CMF in adjuvant chemotherapy for women with early breast cancer. This report details longer foll...

Descripción completa

Detalles Bibliográficos
Autores principales: Earl, H M, Hiller, L, Dunn, J A, Vallier, A-L, Bowden, S J, Jordan, S D, Blows, F, Munro, A, Bathers, S, Grieve, R, Spooner, D A, Agrawal, R, Fernando, I, Brunt, A M, O'Reilly, S M, Crawford, S M, Rea, D W, Simmonds, P, Mansi, J L, Stanley, A, McAdam, K, Foster, L, Leonard, R CF, Twelves, C J, Cameron, D, Bartlett, J MS, Pharoah, P, Provenzano, E, Caldas, C, Poole, C J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494422/
https://www.ncbi.nlm.nih.gov/pubmed/23047592
http://dx.doi.org/10.1038/bjc.2012.370

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3494422/
https://www.ncbi.nlm.nih.gov/pubmed/23047592
http://dx.doi.org/10.1038/bjc.2012.370

Ejemplares similares